VeriSIM Life

?VeriSIM Life today announced that its platform has once again been named "Predictive Analytics Solution of the Year" by the 2024 BioTech Breakthrough Awards! Read more: bit.ly/3CDDj0D

We would like to thank Jo Varshney, CEO of VeriSIM Life, for her participation and presence at the Ilmac Conference. ???? Listen to her statement about the event and the importance of each industry: https://lnkd.in/eQfGwW-n We were delighted that Jo made the journey from California USA to Lausanne, Switzerland. Thank you! ???? You can find all the statements on Ilmac Lausanne online: https://lnkd.in/eeqM8Ct2 ?? Register your company for Ilmac Basel 2025 and benefit from the early bird discount until December 31: https://lnkd.in/e4pBbD4x #ilmac #lifesciences #chemistry #biotechnology #laboratory

Missed the news that VeriSIM Life won Gold for Most Innovative Company of the Year in the Stevie Awards for Women in Business? One judge said, "VeriSIM Life has made impressive strides in the field of drug development, particularly in addressing the inefficiencies of the traditional drug discovery process. The fact that they have achieved significant partnerships, is a testament to the effectiveness of their technology. Their ability to develop PT001 in less than three years, which is significantly faster than the industry standard, showcases their innovative capabilities." Read the announcement here:?bit.ly/4fFyimr

Check out the recent episode of the Impact AI podcast with Heather Couture, PhD from Pixel Scientia Labs, "De-Risking Drug Translation with Jo Varshney from VeriSIM Life." The podcast touches on Dr. Varshney's background, VeriSIM Life's mission and other hot topics around hybrid AI. Listen now: https://bit.ly/3O2ZYWH

As machine learning becomes increasingly widespread, AI holds the potential to revolutionize drug development, making it faster, safer, and more affordable than ever. In this episode, I'm joined by Jo Varshney, Founder and CEO of VeriSIM Life, to explore how her company is transforming drug translation through hybrid AI. With her unique blend of expertise as a veterinarian and computer scientist, Jo leverages biology, chemistry, and machine learning knowledge to tackle the translational gap between animal models and human patients. You’ll learn about VeriSIM Life’s innovative approach to overcoming data limitations, synthesizing new data, and applying ML models tailored to various diseases, from rare conditions to neurological disorders. Jo also reveals VeriSIM’s unique translational index score, a tool that predicts clinical trial success rates and helps pharma companies identify promising drugs early and avoid costly failures. For anyone curious about the future of AI in healthcare, this episode offers a fascinating glimpse into the world of biotech innovation. To discover how VeriSIM Life’s technology is poised to bring life-saving treatments to patients faster and more safely than ever before, be sure to tune in today! Subscribe on your favorite podcast platform to be notified about new episodes every Monday. https://lnkd.in/erp4sUCj #ImpactAI #machinelearning #drugdiscovery #translationalmedicine

VeriSIM Life is excited to announce that we have won Gold for Most Innovative Company of the Year in the Annual Stevie? Awards for Women in Business! Read our announcement:?bit.ly/4fFyimr

VeriSIM Life is excited to be at AAPS PharmSci 360 this week - don't miss our Head of Biosimulations, Dr. Divesh Bhatt present, "AI-Driven Innovations for Advanced Pharmaceutical Formulation Development" on October 22nd at 10:30 AM. Additionally, be sure to reserve your space to speak to a team member of VeriSIM Life to find out how our BIOiSIM platform minimizes translational risk and enables research teams to make early, data-driven decisions. Book your meeting now: https://hubs.li/Q02V9Q_v0

There is a growing interest in using computational approaches to predict drug-induced liver injury (DILI.) However, these methods fail to adequately consider detailed aspects of interspecies differences in drug pharmacological behavior, gene dysregulation due to the drugs, accurate drug chemistry, and integration of specific liver toxicity pathways. In this case study, VeriSIM Life performed research aimed to solve these problems by leveraging knowledge-AI hybrid technology (hybrid AI) to provide robust solutions even in severely data-limited scenarios. Read more: bit.ly/3Uj7q3z

In this case study, VeriSIM Life utilized its hybrid AI platform, BIOiSIM, to address the challenges of limited and missing data from clinical trials. The approach included imputing missing biomarker data utilizing hybrid AI models to reduce missing values with high robustness and enriching patient populations, including underrepresented groups, through AI-driven virtual patient generation (with 10,000 virtual patients generated). Learn more: https://hubs.li/Q02TKZ_b0